New Data Supports GlucoModicum's Needle-Free Glucose Monitor

The Helsinki-based start-up has released data demonstrating the efficacy of its magnetohydrodynamic technology and how it could be used to measure blood glucose levels.

A prototype version of GlucoModicum's Talisman device • Source: GlucoModicum

GlucoModicum, developers of a non-invasive method for measuring blood glucose, are touting new data that show glucose measurements taken with the company’s non-invasive magnetohydrodynamic (MHD) sampling technology correlate with capillary blood glucose samples.

The results show a mean absolute relative difference  the difference between the measured and the real value  of 12.9%.

This value puts the technology within 10-15% of readings produced by current in-use continuous glucose monitors, like Dexcom’s G7 or Abbott’s FreeStyle Libre 3.

More from Diagnostics

More from Device Area